Navigation Links
Genmab Announces Year End 2007 Financial Results
Date:3/31/2008

three milestones in Roche collaboration

Gained rights to HuMax-CD4 and HuMax-TAC from Merck Serono and HuMax-IL8

through asset exchange with Medarex

Commenced seven new studies:

HuMax-EGFr - Phase III front line head and neck cancer study by DAHANCA

and Phase II non small cell lung cancer study

HuMax-CD20 - Phase II front line CHOP combination study in follicular

non-Hodgkin's lymphoma, 2 RA Phase III studies, Phase II relapsed

diffuse large B-cell lymphoma study

HuMax-CD38 Phase I/II multiple myeloma study

Achieved positive clinical trial results:

HuMax-CD20 Phase II RA data

Final HuMax-CD4 Phase II cutaneous T-cell lymphoma (CTCL) data

R1507 Phase I sarcoma data

Presented pre-clinical data:

Positive data for HuMax-HepC, HuMax-EGFr and HuMax-CD20

Unique mechanisms of action of HuMax-CD4 and HuMax-EGFr

Financial Highlights:

Cash position increased for fourth consecutive year

Achieved membership in OMXC20 index on the OMX Nordic Exchange

Copenhagen

2008 Guidance

We expect to significantly expand development in 2008 in our clinical and pre-clinical programs, including plans to initiate 17 new clinical studies, filing our first biologics license application and selecting two new clinical candidates. We will pay development costs for the new and ongoing pivotal studies in HuMax-CD4 and HuMax-EGFr. Under our collaboration with GSK, we will fund half the development costs for the trials with HuMax-CD20. We expect to continue our increasing level of discovery and pre-clinical work in 2008, developing antibody products for a variety of new and existing disease targets. Finally, the 2008 projections include operating costs from the newly acquired antibody manufacturing facility.

Due to these expanded activities, Genmab's operating costs are expected to be higher in 2008 than in 2007. In combination with increasing re
'/>"/>

SOURCE Genmab A/S
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5

Related biology technology :

1. Genmab Announces 2007 First Half Year Results
2. Genmab Announces Encouraging Preclinical Data for ofatumumab
3. Genmab Discloses Target and Development Plans for HuMax-Inflam
4. Genmab Announces Asset Exchange Agreement
5. Genmab Amends Ofatumumab Pivotal Study in NHL to Single Arm Study
6. Genmab A/S - Company Announcement
7. Genmab Amends HuMax-CD4 Pivotal Study in CTCL
8. Phase I Results Announced for R1507 From Genmabs Collaboration With Roche
9. Genmab Announces Results for the First Nine Months of 2007
10. Genmab Announces Update on Recruitment of Patients in ofatumumab CLL Pivotal Study
11. Fourth Genmab Antibody Developed Under Roche Collaboration to Enter Clinic
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/16/2009)... at Hahnemann among the Best in the Nation ... University Hospital proudly announces it has been granted ... (ANCC) Magnet Recognition Program(R). Magnet(R) is one of ... medical center can achieve, and places Hahnemann among ... that have achieved this prestigious distinction. ,, At ...
(Date:12/16/2009)... biotechnology company,s revenues increase 22% for fiscal 2009; ... 2010 , TORONTO, Dec. 16 /PRNewswire-FirstCall/ - Microbix ... virology and biological technologies, today reported financial results ... fiscal year ended September 30, 2009, Microbix reported ... the same period in 2008. For fourth-quarter 2009, ...
(Date:12/16/2009)... Nu-Tek BioSciences, LLC introduces HSP-A Soy Peptone. HSP A has ... , ... (PRWEB) December 16, 2009 -- Nu-Tek BioSciences, ... by introducing HSP-A Soy Peptone. HSP-A, previously manufactured by Nutricepts, ... is proven to improve growth rates and yields. HSP-A has ...
(Date:12/15/2009)... Sky One,Medical, Inc. ("China Sky One Medical" or ... integrated pharmaceutical company developing and producing,over-the-counter drugs in ... the Company has 30 medicines that will be ... Medical Insurance, Industrial Injury Insurance,and Maternity Insurance Medicine ... medicines treat a variety of common ailments and ...
Breaking Biology Technology:Hahnemann University Hospital Granted Magnet(R) Status 2Hahnemann University Hospital Granted Magnet(R) Status 3Microbix' Pipeline Set To Reach Milestones In 2010 2Microbix' Pipeline Set To Reach Milestones In 2010 3Microbix' Pipeline Set To Reach Milestones In 2010 4Microbix' Pipeline Set To Reach Milestones In 2010 5Microbix' Pipeline Set To Reach Milestones In 2010 6Microbix' Pipeline Set To Reach Milestones In 2010 7Microbix' Pipeline Set To Reach Milestones In 2010 8China Sky Medical, Inc. Has 30 Medicines that will Be Included in China's National Insurance Directory 2China Sky Medical, Inc. Has 30 Medicines that will Be Included in China's National Insurance Directory 3
... (Nasdaq: PRXL ), a leading global ... a Vice President and General,Manager in the ... more than 20 years of experience in ... Ms. Fisher leads a global,team of experts ...
... with Amgen- ... 9:00 A.M. EDT-, MONTVALE, N.J., March 12 ... it has realigned,its operations, reallocated its resources and extended ... The Company will,focus its near-term and mid- term efforts ...
... Utilizes Revolutionary Electrotherapy to Improve Healing ... ... 12 Kingfisher Americas,a healthcare company focused on improving patient ... Healthcare, has,received CE mark for its KFH Novo medical device, ...
Other Biology Technology:PAREXEL Appoints Leading Biopharmaceutical Marketing Expert Jacque Fisher to Medical Communications Services Executive Team 2PAREXEL Appoints Leading Biopharmaceutical Marketing Expert Jacque Fisher to Medical Communications Services Executive Team 3PAREXEL Appoints Leading Biopharmaceutical Marketing Expert Jacque Fisher to Medical Communications Services Executive Team 4Memory Pharmaceuticals Refocuses to Advance Development and Clinical Programs 2Memory Pharmaceuticals Refocuses to Advance Development and Clinical Programs 3Memory Pharmaceuticals Refocuses to Advance Development and Clinical Programs 4Memory Pharmaceuticals Refocuses to Advance Development and Clinical Programs 5Kingfisher Healthcare Receives European CE Mark for Next Generation Wound Healing Device 2
(Date:12/16/2009)... sediment cores is illuminating the environmental conditions that prevailed ... history. , Around 55 million years ago at the ... believed to have been free of ice. But by ... sheets covered Antarctica and continental ice had developed on ... conditions resulted from decreasing greenhouse gas concentrations and changes ...
(Date:12/16/2009)... a high priority for grape growers in the southern Napa Valley, ... irrigated to make it through the growing season. But Stanford researchers ... the vines zips right by the plants, hardly even pausing. ... is applied is lost below the vine rooting zone and does ... Hinckley, who worked on the project for her PhD thesis in ...
(Date:12/16/2009)... billion years before humans showed up, and they,ll probably ... they may have something to teach us. , New ... Ben-Jacob of the Raymond and Beverly Sackler School of ... presents compelling evidence to suggest there may be good ... the swine flu H1N1 shot. , In research published ...
Breaking Biology News(10 mins):From greenhouse to icehouse -- reconstructing the environment of the Voring Plateau 2Lost water of the Napa Valley vineyards 2Lost water of the Napa Valley vineyards 3Lost water of the Napa Valley vineyards 4Bacteria wouldn't opt for a swine flu shot 2Bacteria wouldn't opt for a swine flu shot 3BioMarin to Present at the Baird Healthcare Conference 13799 1BioMarin to Present at the Baird Healthcare Conference 13799 2Special Needs Equipment Rentals Save the Day for Travelers with Physical Disabilities 55997 1Special Needs Equipment Rentals Save the Day for Travelers with Physical Disabilities 55997 2Special Needs Equipment Rentals Save the Day for Travelers with Physical Disabilities 55997 3MarketsandMarkets 3A Global Emerging Lighting Technologies Market Worth US 24112 2 Billion by 2014 55993 1MarketsandMarkets 3A Global Emerging Lighting Technologies Market Worth US 24112 2 Billion by 2014 55993 2MarketsandMarkets 3A Global Emerging Lighting Technologies Market Worth US 24112 2 Billion by 2014 55993 3
... press release is available in German . ... UFZ German scientist found that the worldwide economic ... bees mainly, was 153 billion in 2005 for the ... to 9.5% of the total value of the world ...
... PHOENIX, Ariz. Sept. 15, 2008 Investigators at ... link between the brain protein KIBRA and Alzheimer,s disease, ... for this memory-robbing disorder. , The new discovery builds ... journal Science, which showed a genetic link between KIBRA ...
... combination of cutting-edge technologies to scan the human ... UPMC have identified a genetic mutation that identifies ... a single nucleotide polymorphism (SNP), the genetic mutation ... developed to search the human genome, according to ...
Other Biology News:Economic value of insect pollination worldwide estimated at 153 billion euros 2Economic value of insect pollination worldwide estimated at 153 billion euros 3International TGen-led team finds link between brain protein and Alzheimer's disease 2International TGen-led team finds link between brain protein and Alzheimer's disease 3International TGen-led team finds link between brain protein and Alzheimer's disease 4Children's Hospital researchers identify genetic mutation that may predict organ rejection 2
... The Bio-Plex maintenance, calibration, and ... custom 96-well plate used for ... calibration procedures using the Bio-Plex ... plate is for use with ...
Methylation analysis of gene promoters using bilsulfite treatment of DNA and comparative DNA sequence analysis. Probe design and PCR included....
... a high quality whole genome sequencing service. ... costs allow even the smallest of laboratories ... key features which set our whole genome ... construction strategies, proprietary assembly software, rapid project ...
Great for biotinylating DNA/RNA probes...
Biology Products: